Seqirus said it has achieved an industry first by producing a cell-based influenza vaccine on a commercial scale using a virus grown in cells.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-…

Judging from IDEXX’s third-quarter earnings, it’s reaping the rewards from being an early mover in the rapidly growing market for animal diagnostics.

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint…

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--…